Neurologic Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 30: | Line 30: | ||
== Complications due to medication interaction == | == Complications due to medication interaction == | ||
==== 1. Statin induced myotoxicity ==== | |||
* Myalgia, myopathies, rhabdomyolysis | |||
==== 2. 2nd and 3rd degree atrioventricular block ==== | |||
* Lopinavir/ Ritonavir (Kaltera) (400 mg/100 mg) | |||
==== 3. Prolong QTc interval ==== | |||
* Chloroquine/Hydroxychloroquine | |||
==== 4. Myelotoxicity ==== | |||
* Ribavirin | |||
==== 5. Prolonged PR interval ==== | |||
* Atazanavir | |||
==== 6. Myelosuppression ==== | |||
7. | |||
<br /> | |||
==References== | ==References== | ||
Revision as of 11:04, 23 June 2020
To go to the COVID-19 project topics list, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Rinky Agnes Botleroo, M.B.B.S.
Overview
Pathophysiology of the Complications in the Nervous System
Mechanism of targetting the Nervous System
Complications in the Central Nervous System
Cerebrovascular Accident/Stroke
- Hemorrhagic
- Ischaemic
Acute Encephalitis
Viral Meningitis
Epileptic Seizures
Encephalopathy
Headache
Complications in the Peripheral Nervous system
Guillain-Barre syndrome
Anosmia
Acute Myelitis
Miller Fischer Sydrome
Polyneuritis Cranialis
Complications due to medication interaction
1. Statin induced myotoxicity
- Myalgia, myopathies, rhabdomyolysis
2. 2nd and 3rd degree atrioventricular block
- Lopinavir/ Ritonavir (Kaltera) (400 mg/100 mg)
3. Prolong QTc interval
- Chloroquine/Hydroxychloroquine
4. Myelotoxicity
- Ribavirin
5. Prolonged PR interval
- Atazanavir
6. Myelosuppression
7.